ClinicalTrials.gg
CompletedNCT01529684Updated Nov 7, 2024

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

A Phase 1 interventional study of radio-labeled OSI-906 and OSI-906 in Advanced Solid Tumors and Pharmacokinetics of 14C-OSI-906, sponsored by Astellas Pharma Global Development, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics, in particular the routes of excretion and extent of metabolism of OSI-906 after a single oral dose of 14C-labeled OSI-906. Subjects with Advanced Solid Tumors may participate and then continue into the Optional Treatment Phase.

Read the detailed description

This study includes two parts: Part A

Subjects will be admitted to the clinical research unit on Day -1 and remain confined to the unit until post dosing discharge criteria are met up to a maximum of 10 days. On Day 1, subjects will receive a single oral dose of 14C-labeled OSI-906.

Part B (optional)

Once the subject has completed part A, the subject may elect to continue participation in Part B. Subjects will receive OSI-906 (non-radiolabeled) twice daily by mouth. Subjects will be seen for scheduled visits every 7 days for the first 36 days and then every 21 days.

02

Conditions studied

  • Advanced Solid Tumors
  • Pharmacokinetics of 14C-OSI-906

Browse trials for

Keywords

  • oncology patients
  • Metabolic profile of 906
  • OSI-906
  • mass balance
  • Pharmacokinetics of 14C-OSI-906
  • Cancer, solid tumors
  • Absorption, Metabolism, and Excretion of OSI-906
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 5 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has or cytologically confirmed diagnosis of advanced solid tumor (measurable or non-) for which no conventional therapy is available
  • The subject has an (ECOG) Performance Status (PS) ≤ 2
  • The subject has a predicted ≥12 weeks
  • The subject has a fasting glucose ≤125 mg/dL (7 mmol/L) at Screening, Day -1 and pre-dose Day 1
  • The subject has adequate organ function defined by the following laboratory parameters:

    • (ANC) ≥1.5 x 10 9/L
    • count ≥100 x 10 9/L
    • total ≤1.5 x (ULN)
    • (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN if subject has documented liver
    • serum creatinine ≤1.5 x ULN
    • potassium, calcium, and magnesium within normal limits or determined by the investigator to be not (NCS)
  • The subject has a negative cotinine test
  • If male, is surgically sterile, or is using a medically acceptable method to prevent pregnancy and agrees to continue using this method while participating in the study and for 90 days after the last dose of study medication
  • If female, the subject is surgically sterile or status post hysterectomy, , or is using 2 forms of medically acceptable methods of , one of which must be a barrier method to prevent pregnancy and agrees to continue using this method from screening until 90 days after the last dose of study medication
  • If female, the subject must not be breastfeeding at Screening, during the study period and for 90 days after last dose of study drug administration
  • If female, the subject must not donate ova starting at Screening, and throughout the study period and for 90 days after last dose of study drug administration
  • Female subject of child bearing potential has a negative pregnancy test at Screening and Day -1

Exclusion criteria

Exclusion Criteria:

  • The subject has Type 1 or Type 2 diabetes mellitus currently requiring insulinotropic or insulin therapy
  • The subject has a history of poorly controlled gastrointestinal disorder (s) that could affect the absorption or metabolism of study drug
  • The subject has used IGF-1R inhibitor therapy in last 6 months
  • The subject has hepatocellular carcinoma
  • The subject has used a CYP1A2 inhibitor or inducer within 14 days prior to Day 1
  • The subject has used drugs with a risk of causing prolongation and Torsade de Pointes (TdP) within 14 days prior to Day 1
  • The subject has a history (within last 6 months) of significant cardio-vascular disease
  • The subject has a history (within the last 6 months) of significant arrhythmia disease, unless the disease is well-controlled with medication per the Principal Investigator's clinical judgment
  • The subject has had major surgery ≤ 3 weeks prior to Day 1
  • The subject has had radiation ≤ 3 weeks prior to Day 1
  • The subject has had chemotherapy ≤ 3 weeks prior to Day 1
  • The subject has participated in a radiolabeled study in the last 12 months
  • The subject has a history of cerebrovascular accident (CVA) within 6 months prior to Day 1 or that resulted in ongoing neurologic instability
  • The subject has an active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to Day 1) that would impair the ability of the subject to receive study drug
  • The subject has participated in any interventional clinical study within 21 days or has been treated with any drugs within 30 days or 5 half lives whichever is longer, prior to the initiation of Screening
  • The subject has a history of any psychiatric condition that might impair the subject's ability to understand or to comply with the requirements of the study or to provide
  • The subject is pregnant or lactating
  • The subject has symptomatic that are not stable, require , or that have required radiation and/or other related treatment, (i.e., anti-epileptic medication) within 28 days prior to Day 1
  • The subject has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    OSI-906

    Two Parts: Part A: 14C-labeled OSI-906 Part B: (Optional) OSI-906 (non-labeled)

    Drug: radio-labeled OSI-906 · Drug: OSI-906

Interventions

  • Drugradio-labeled OSI-906

    Part A: oral solution of 14C-OSI-906

  • Part B: oral tablets OSI-906

06

What researchers measure

Primary outcomes

  1. Radioactivity in whole blood and plasma

    Outcome measure for Part A: Area under the time concentration curve extrapolated to infinity (AUCinf), AUC from time of dosing to last quantifiable time point (AUClast), Maximum Plasma Concentration (Cmax), Time to maximum concentration (Tmax), Terminal half-life (t 1/2), Apparent Body Clearance after dosing (CL/F), and Apparent volume of distribution (Vz/F)

    Time frame: Up to 10 days from time of receipt of 14C-labeled OSI-906

  2. Radioactivity ratio in blood/plasma

    Outcome Measure for Part A of OSI-906 distribution between cellular components and plasma

    Time frame: Up to 10 days from time of receipt of 14C-labeled OSI-906

  3. Excretion ratio and cumulative excretion of radioactivity in urine and feces

    Outcome measure for Part A

    Time frame: Up to 10 days from time of receipt of 14C-labeled OSI-906

  4. Composite of Pharmacokinetics of OSI-906 in plasma: AUC inf, AUC last, C max, t max, t 1/2, CL/F, and Vz/F

    Outcome measure for Part A

    Time frame: Up to 10 days from time of receipt of 14C-labeled OSI-906

  5. Composite of Pharmacokinetics of OSI-906 in urine: Cumulative amount of drug excreted into urine, feces or bile up to collection time of last measurable concentration (Ae last), Renal Clearance (CL R), and percentage of dose excreted (Ae last%)

    Outcome measure for Part A

    Time frame: Up to 10 days from time of receipt of 14C-labeled OSI-906

Secondary outcomes

  1. Metabolic Profile: Profiling of possible metabolites in OSI-906 plasma, urine, and feces

    Outcome measure for Part A

    Time frame: Up to 10 days from time of receipt of 14C-labeled OSI-906

  2. Safety as assessed by recording adverse events, laboratory assessments and vital signs, and electrocardiograms (ECGs)

    Outcome measures for Part A and Part B

    Time frame: For Part A: Days 1-10 and/or 30 days post treatment visit. For Part B: Treatment Period 1 (TP1) through 30 day post treatment visit (up to two years)

07

Study locations

2 sites
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
  • Comprehensive Clinical Development NW, Inc.
    Tacoma, Washington 98418, United States
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Dec 2012, 8 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 8 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2012
First posted
Feb 9, 2012
StartActual
Mar 19, 2012
Primary completionActual
Dec 8, 2012
CompletionActual
Feb 20, 2013
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01529684
Responsible party
Sponsor
First posted
Feb 9, 2012
Start date
Mar 19, 2012
Primary completion
Dec 8, 2012
Completion
Feb 20, 2013
Last update
Nov 7, 2024

Study contacts

Medical Director
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linsitinib

Start the discussion